Our data highlight the prognostic value of EphA2 in bladder cancer as well as the therapeutic potential of the EphA2-targeting antibody-directed nanotherapeutic EphA2-ILs-DTXp, supporting its clinical exploration as a novel targeted therapy for the treatment of urothelial carcinoma. Here, EPHA2 is linked to urinary bladder carcinoma.